Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| SCBGENOME(SSFE) | +84.46% | +8.18% | +11.73% | +2.83% | +41.58% | +76.38% | +76.76% | +128.30% | +57.33% |
| ASP-IHEALTH | +15.67% | +2.35% | +6.63% | −0.47% | +0.07% | +15.64% | +24.24% | +65.21% | +67.60% |
| BCAP-XHEALTH | +20.18% | +1.90% | +5.53% | +0.43% | +6.60% | +23.32% | +15.56% | +26.68% | +11.18% |
| SCBIHEALTH(E) | +10.12% | +3.11% | +5.92% | +4.67% | +7.71% | +22.19% | +14.90% | +25.91% | −4.01% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
| ASP-IHEALTH | BCAP-XHEALTH | |
|---|---|---|
| Held by both | ||
 Revolution Medicines | 4.36% | 2.03% |
 Twist Bioscience | 2.69% | 1.92% |
 10x Genomics | 2.62% | 1.87% |
 Praxis Precision | 3.47% | 1.62% |
 BridgeBio Pharma | 2.94% | 1.37% |
 argenx | 2.86% | 1.33% |
 Gilead Sciences | 2.84% | 1.32% |
 Travere Therapeutics | 2.61% | 1.22% |
| Only in ASP-IHEALTH | ||
 PTC Therapeutics | 2.37% | N/A |
 Vertex Pharmaceuticals | 2.35% | N/A |
| Only in BCAP-XHEALTH | ||
 Tempus AI | N/A | 1.66% |
 Eli Lilly and Co | N/A | 1.21% |
30 Dec 2025 → 28 Oct 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| SCBGENOME(SSFE) | +84.46% | 42.00% | 2.01 |
| BCAP-XHEALTH | +20.18% | 19.56% | 1.03 |
| ASP-IHEALTH | +15.67% | 24.98% | 0.63 |
| SCBIHEALTH(E) | +10.12% | 17.35% | 0.58 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | SCBGENOME(SSFE) | ASP-IHEALTH | BCAP-XHEALTH | SCBIHEALTH(E) |
|---|---|---|---|---|
Fund details | ||||
| Fund size | 3.27 million | 138 million | 470 million | 30.55 million |
| Inception date | 20 Aug 2021 | 29 Mar 2019 | 14 May 2021 | 29 Jun 2021 |
| Master fund | กองทุน ARK Genomic Revolution ETF | กองทุนที่ลงทุนหลายกอง (JHHBIU2 LX, ARKG US) | กองทุนที่ลงทุนหลายกอง | BNP Paribas Funds Health Care Innovators |
| Dividend policy | Pays | Does not pay | Does not pay | Does not pay |
Risk and currency hedging | ||||
| Risk level | 7 | 7 | 6 | 7 |
| Hedging policy | Hedged at the manager's discretion | Almost fully hedged | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | 57.68% | 100.14% | N/A | 82.39% |
Minimum purchase and redemption | ||||
| First purchase | 1 THB | 1,000 THB | 500 THB | 1 THB |
| Subsequent purchase | 1 THB | 1,000 THB | 500 THB | 1 THB |
| Redemption (amount) | No minimum | No minimum | No minimum | 1 THB |
| Redemption (units) | No minimum | No minimum | No minimum | No minimum |
| Balance (amount) | No minimum | No minimum | No minimum | 1 THB |
| Balance (units) | No minimum | No minimum | No minimum | No minimum |
Order cut-off and redemption payment | ||||
| Buy before | 15:30 | 15:30 | 15:30 | 15:30 |
| Redeem before | 15:30 | 15:30 | 15:30 | 15:30 |
| Redemption paid | T+4 | T+5 | T+3 | T+4 |
